Skip to content
  • Home
  • World News
  • Business
  • Aviation
195 news

195News

All the news that's fit to print

  • Home
  • World News
  • Business
  • Aviation
  • Toggle search form
  • War Day 156: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych  & #Feygin
    War Day 156: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych & #Feygin World News
  • InprimepayThe London-based platform that assists Italian stores with innovative payment systems linked to digitalization Business
  • Sculpture Hospitality Hosts 22nd Annual Convention Following Covid-Related Hiatus Business
  • A Journey in Precision Automation Aviation
  • RISE Exhibits & Environments Inspires Innovative Custom Trade Show Exhibit Designs Business
  • THE ONLY ALL-IN-ONE SOLUTION BUILT FOR RESTAURANTS THAT HELP THEM MAKE MORE MONEY World News
  • Analyzing Growth Drivers, Market Share, Segments, and Emerging Trends World News
  • War Day 126: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych & #Feygin World News

IF YOUR FINANCIAL ADVISOR RECOMMENDED ESSA PHARMA INVESTMENTS PLEASE CONTACT KT LAW

Posted on February 16, 2025 By NewsEditor

If you suffered losses in ESSA Pharma, Inc., Contact KT Law

KlaymanToskes Investigates on Behalf of Investors Who Were Recommended ESSA Pharma, Inc. Investments By Their Broker/Advisor

ESSA Pharma, Inc. (NASDAQ:EPIX)

NEW YORK, NY, UNITED STATES, February 4, 2025 /EINPresswire.com/ — National investment loss and securities lawyers KlaymanToskes issues an important notice to investors who suffered significant losses in ESSA Pharma, Inc. (NASDAQ: EPIX). The law firm urges customers of brokerage firms and financial advisors who suffered investment losses in excess of $100,000 in ESSA Pharma, Inc. to contact the firm immediately at 888-997-9956. Investors with self-directed accounts who did not rely on the advice of a financial advisor are not eligible for our representation.

KlaymanToskes is investigating brokerage firms and financial advisors that recommended investments in ESSA Pharma, Inc. to their customers. On October 31, 2024, ESSA Pharma announced the termination of its Phase 2 M-E Combination Study, and disclosed that it planned to terminate all other company-sponsored and investigator-sponsored clinical studies involving masofaniten. Following this announcement, ESSA’s stock price plummeted by 73.08%, dropping from $5.20 per share to $1.40 per share on November 1, 2024.

Our investigation has led the law firm to believe that investment firms and their financial advisors may have failed to act in the best interest of their customers, and misrepresented the risk-factors related to investments in ESSA Pharma, in addition to failing to conduct due diligence on ESSA Pharma’s investment offering, leading to unsuitable recommendations.

Financial advisors and their firms may be held liable for any losses incurred by their customers in the event of failure to act in the best interest of the customer, unsuitable investment recommendations, misrepresentations or omissions of material facts, and/or an overconcentration of the customer’s portfolio in one particular investment, class, or market sector. Further, financial professionals and their firms cannot disregard a customer’s risk-tolerance when making investment recommendations.

Depending on your circumstances, you may be entitled to recover your losses through FINRA arbitration, which may result in a greater and additional recovery to solely participating and waiting for any recovery in any class action lawsuit.

Investors who suffered losses over $100,000 in ESSA Pharma, Inc. are encouraged to contact attorney Steven D. Toskes at (888) 997-9956 or by email at [email protected] in furtherance of our investigation. Investors with self-directed accounts who did not rely on the advice of a financial advisor are not eligible for our representation.

About KlaymanToskes

KlaymanToskes is a leading national securities law firm which practices exclusively in the field of securities arbitration and litigation on behalf of retail and institutional investors throughout the world in large and complex securities matters. The firm has recovered over $250 million in FINRA arbitrations and over $350 million in other securities litigation matters. KlaymanToskes has office locations in California, Florida, New York, and Puerto Rico.

Contact

Steven D. Toskes, Esq.
KlaymanToskes, P.A.
+1 888-997-9956
[email protected]

Legal Disclaimer:

EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

You just read:

News Provided By

February 04, 2025, 15:56 GMT


EIN Presswire’s priority is author transparency. We do our best to weed out false and misleading content. The content above is
the sole responsibility of the author who makes it available. If you have any complaints, kindly contact the author above.

Article originally published on www.einpresswire.com as IF YOUR FINANCIAL ADVISOR RECOMMENDED ESSA PHARMA INVESTMENTS PLEASE CONTACT KT LAW

Business

Post navigation

Previous Post: Saudia’s Chief Guest Experience Officer, Mr. Rossen Dimitrov, to Deliver Keynote at Airport Expansion Conference 2025
Next Post: Fast Delivery Services To Gain A Competitive Edge

Related Posts

  • Cheba Hut San Diego-SDSU is Moving to an Epic New Location, Opening Monday, March 6 Business
  • MASS Group Announces New Integration With FEIG Electronics Business
  • Adit EdTech Acquisition Corp. Transfers Listing to NYSE American LLC Business
  • Food Preservatives Market Crosses $3,671.7 Million by 2031 with a Masterstroke CAGR of 3.4% Business
  • Brenda Maher Named President of Berkshire Hathaway HomeServices New England and New York Properties Business
  • Edward Andrews Business Consultants Achieves Record Client Growth Business
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
« Oct    
last celebrity gossip
Gossip Stone - celebrity life and gossip

Recent Posts

  • Atenolol Market Outlook Report Including Segment Analysis and Strategic Industry InsightsNovember 18, 2026
  • Abdullah Al Junayed Releases Open Research Dataset on Machine FatigueNovember 18, 2026
  • The At-Home Genetic Testing Market Is Projected to Grow at a 15.5% CAGR by 2030November 17, 2026
  • MESSCAN Launches TC25 Compact Laser Distance Sensor for OEM Optical and Electro-Optical IntegrationNovember 17, 2026
  • The Assisted Reproductive Technology Market is to grow at a CAGR of 8.9%, reaching a value of $56.96 billion by 2030.November 16, 2026
Brand Values Content
VUGA Enterprises - media network PR & Marketing
  • Marketing Executives Leverage Newswire’s Media Advantage Platform to Drive Online Visibility Through High-Tech, High-Touch Approach Business
  • War Day 220: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych & #Feygin
    War Day 220: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych & #Feygin World News
  • War Day 274: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych & #Feygin
    War Day 274: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych & #Feygin World News
  • eRank Reports on 2022 Etsy Shopper Buying Habits Business
  • Recent Poll by Tulchin Research Shows the Los Angeles Sheriff’s Race is in a Dead Heat With 20% of Angelenos Undecided World News
  • CAPTAIN LAURA EINSETLER SELECTED AS MOST INSPIRATIONAL AIRLINE PILOT OF THE DECADE BY IAOTP World News
  • DHS Announces Results of 2022 Invent2Prevent Final Competition World News
  • Completion of The Ritz-Carlton Residences, Mexico City Marked by Release of Last Units Business
aerospace company
stem cell clinic in kiev
medical spa in miami
Fashion TV free

Copyright © 2026 195 News. All Rights Reserved by Coolaser

Powered by .